Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord

• Published in: Internal medicine journal 2013-04, Vol.43 (4), p.430-439
• Main Authors: Manochantr, S., U-pratya, Y., Kheolamai, P., Rojphisan, S., Chayosumrit, M., Tantrawatpan, C., Supokawej, A., Issaragrisil, S.
• Format: Article
• Language: English
• Subjects: amnion; Amnion - cytology; Amnion - immunology; Cell Proliferation - drug effects; Cells, Cultured; Female; Humans; Immunosuppression - methods; immunosuppressive; Immunosuppressive Agents - immunology; Immunosuppressive Agents - pharmacology; Mesenchymal Stromal Cells - immunology; MSC; placenta; Placenta - cytology; Placenta - immunology; Pregnancy; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; umbilical cord; Umbilical Cord - cytology; Umbilical Cord - immunology; Wharton Jelly - immunology; Wharton's jelly
• ISSN: 1444-0903; 1445-5994
• DOI: 10.1111/imj.12044

Background The role of bone marrow‐derived mesenchymal stromal cells (BM‐MSC) in preventing the incidence and ameliorating the severity of graft‐versus‐host disease (GvHD) has recently been reported. However, as the collection of BM‐MSC is an invasive procedure, more accessible sources of MSC are desirable. Aim This study aimed to explore the alternative sources of MSC from amnion, placenta, Wharton's jelly and umbilical cord, which are usually discarded. Methods MSC from those tissues were isolated using mechanical dissociation and enzymatic digestion. Their capacity for proliferation and differentiation, and ability to suppress alloreactive T‐lymphocytes were studied and compared with those of BM‐MSC. Results MSC derived from amnion, placenta, Wharton's jelly and umbilical cord were similar to BM‐MSC regarding the cell morphology, the immunophenotype as well as the differentiation ability. These MSC also elicited a similar degree of immunosuppression, as evidenced by the inhibition of alloreactive T‐lymphocytes in the mixed lymphocyte reaction, compared with that of BM‐MSC. MSC from umbilical cord and Wharton's jelly had a higher proliferative capacity, whereas those from amnion and placenta had a lower proliferative capacity compared with BM‐MSC. Conclusion The results obtained from this study suggest that MSC from amnion, placenta, Wharton's jelly and umbilical cord can therefore be potentially used for substituting BM‐MSC in several therapeutic applications, including the treatment of GvHD.